PBMs will have to display TrumpRx drug prices, while Bristol's Zenbexus gains accelerated approval and Novartis wins a UK patent fight over Entresto, in a biotech news roundup.
FDA grants accelerated approval for Replimune’s RP1 (Tudriqev) for advanced melanoma after advisory support, despite prior rejection and trial-design concerns; price not disclosed and confirmatory trials are expected.